Adis JournalsBrowse
Summary Slide.png (122.25 kB)
Download file

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea

Download (122.25 kB)
figure
posted on 2021-01-21, 14:29 authored by Adis journals on behalf of, So-Young Ha, Yoon-Bo Shim, Min-Young Lee, Bon-San Koo, Jae-Hoon Kim, Ja-Young Jeon, Hyun-Jeong Yoo, Young-Joo Kim, Ju-Young Shin, Mi-Hai Park

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History

References

Usage metrics

Read the peer-reviewed publication

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
Rheumatology and TherapyRheumatology and Therapy

Categories

Keywords

Anti-rheumatic agentsCost-benefit analysisQuality-adjusted life-yearsRheumatoid arthritis

Licence

CC BY-NC 4.0

Exports